Core Viewpoint - A securities class action lawsuit has been filed against Boston Scientific Corporation on behalf of investors who purchased its common stock between July 23, 2025, and February 3, 2026, alleging violations of the Securities Exchange Act of 1934 [1][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of Massachusetts, claiming that Boston Scientific and certain senior officers made misrepresentations regarding the company's U.S. electrophysiology segment [5]. - Investors are encouraged to join the class action and can contact the Investor Relations Manager for more information [3][8]. Group 2: Legal Process - Individuals wishing to serve as lead plaintiff must file necessary documents by May 4, 2026, although participation as a class member does not require serving as lead plaintiff [4]. - All legal representation is on a contingency fee basis, meaning shareholders will not incur fees or expenses unless there is a recovery [4]. Group 3: Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 and has a strong track record in class action litigation [6].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Corcept Therapeutics Incorporated on behalf of investors who purchased or acquired the company's common stock between October 31, 2024, and December 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that the defendants made misrepresentations regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, which is Corcept's lead product candidate for multiple indications, including treatment for hypercortisolism [5] Group 2: Legal Actions and Options - Investors who purchased Corcept common stock are encouraged to discuss their legal rights and options, with contact information provided for the Investor Relations Manager [3] - Individuals wishing to serve as lead plaintiff must file necessary papers by April 21, 2026, and can still share in any recovery without serving as lead plaintiff [4]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Soleno Therapeutics, Inc. for alleged misrepresentations regarding the Company's Phase 3 clinical trial program for DCCR, affecting investors who purchased shares between March 26, 2025, and August 4, 2025 [5]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired common stock of Soleno Therapeutics, Inc. during the specified period [1]. - Investors are encouraged to discuss their legal rights and options regarding the lawsuit [3]. - A lead plaintiff must file papers by May 5, 2026, to represent the class in the litigation [4]. Group 2: Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 [6]. - The firm has a strong reputation, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - Driven Brands is facing a class action lawsuit for securities fraud due to significant accounting errors and internal control failures, resulting in a nearly 40% drop in its stock price [2][6]. Company Overview - Driven Brands is an automotive aftermarket services company that operates and franchises various vehicle maintenance and repair brands [4]. Allegations and Financial Impact - The lawsuit claims that Driven Brands issued materially false financial statements and failed to maintain effective internal controls, leading to a stock decline of approximately 39.8% [1][7]. - The company disclosed that it would restate its financial statements for fiscal years 2023 and 2024, along with quarterly and year-to-date financials for 2025, due to numerous material accounting errors [6]. Stock Performance - On February 24, 2026, Driven Brands' stock was priced at $16.61 per share, which dropped to $9.99 per share on February 25, 2026, marking a decline of nearly 40% [6][7]. Legal Proceedings - Investors have until May 8, 2026, to seek appointment as lead plaintiffs in the class action lawsuit pending in the U.S. District Court for the Southern District of New York [3][5].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and its executives for securities fraud, linked to misrepresentations regarding a $1.66 billion Department of Energy loan, resulting in a 17% decline in stock price [1][3]. Group 1: Lawsuit Details - The lawsuit claims violations of federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with a deadline for investors to lead the case set for April 3, 2026 [3]. - The case is currently pending in the U.S. District Court for the Northern District of New York, titled Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. Group 2: Reasons for Stock Decline - On October 7, 2025, Plug Power announced the sudden departure of its CEO and President, leading to a stock price drop of $0.26 per share, or 6.3%, from $4.13 to $3.87 [4]. - Following this, on November 10, 2025, the company suspended activities under the DOE loan program, causing a further decline of $0.09 per share, or 3.4%, from $2.65 to $2.56 [5]. - On November 13, 2025, it was reported that Plug Power confirmed the suspension of plans to construct hydrogen production facilities, resulting in a significant stock drop of $0.48 per share, or 17.6%, from $2.49 to $2.25 [6][7].

Core Viewpoint - Ramaco Resources, Inc. (NASDAQ: METC) is facing a securities fraud lawsuit, with a lead plaintiff deadline set for March 31, 2026, for investors who purchased securities during the Class Period from July 31, 2025, to October 23, 2025 [1]. Summary by Sections Lawsuit Details - The lawsuit alleges that during the Class Period, Ramaco made materially false and misleading statements regarding its mining activities at the Brook Mine, claiming that significant mining had not commenced and that no active work was taking place, leading to an overstatement of development progress [5]. Investor Actions - Investors who purchased Ramaco securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. Law Firm Credentials - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4].

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Trip.com Group Limited (TCOM) Shareholders To Inquire About Securities Fraud Class Action Mar 16, 2026 4:59 PM Eastern Daylight Time Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Trip.com Group Limited (TCOM) Shareholders To Inquire About Securities Fraud Class Action Share LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, annou ...

Core Viewpoint - The company, Aquestive Therapeutics, Inc. (NASDAQ: AQST), faced significant discrepancies between its optimistic projections regarding the Anaphylm regulatory approval and the actual outcomes, leading to a substantial decline in stock value and potential legal repercussions for misleading investors [2][6][8]. Group 1: Company Projections - Throughout the Class Period (June 16, 2025, to January 8, 2026), the company expressed strong confidence in the Anaphylm regulatory path, stating it was "one step closer" to approval after FDA acceptance of the NDA [3] - On August 12, 2025, the company assured investors it was "on track" across all regulatory elements, including FDA review and pre-commercial launch activities [4] - On November 5, 2025, the company reiterated that its NDA was "on track" for the scheduled January 31, 2026 PDUFA goal date, citing "strong execution" [4] Group 2: Actual Outcomes - On January 9, 2026, the FDA identified deficiencies in the NDA that precluded discussions of labeling and post-marketing commitments, indicating that the PDUFA date could not be met [5] - By January 30, 2026, the FDA issued a Complete Response Letter citing multiple failures in human factors validation studies, including usability concerns [5] - The promised FDA approval by January 31, 2026, was replaced with a delay to at least Q1 2027, and the company now faces a resubmission estimated for Q3 2026 [6] Group 3: Legal Implications - The securities action alleges that management was aware of the deficiencies in the Anaphylm NDA while providing misleadingly confident statements to investors, which artificially inflated AQST's stock price [8] - The gap between the company's assurances and the FDA's communications raises serious questions about the accuracy of the information provided to shareholders during the Class Period [6]

Core Viewpoint - Franklin BSP Realty Trust, Inc. (FBRT) significantly reduced its quarterly dividend from $0.355 to $0.20, resulting in a 44% cut and a 14.18% drop in stock price, raising concerns about the company's ability to meet its dividend promises [1][3]. Group 1: Dividend Performance - Management had projected a sustainable quarterly dividend of $0.355 across five consecutive earnings calls, claiming a clear roadmap to full dividend coverage [4]. - The actual quarterly dividend was cut to $0.20, representing a 44% reduction from the promised amount [5]. - The company's diluted earnings per share (EPS) for Q4 2025 fell to $0.13, down from $0.29 in Q4 2024, indicating a decline in financial performance [5]. Group 2: Financial Metrics Comparison - Promised vs. Actual Metrics: - Quarterly Dividend: Promised $0.355, Actual $0.20 [5]. - REO Resolution: Management claimed a quick resolution, but it took longer than planned [5]. - Distributable Earnings Path: Management indicated a clear path to coverage, but actual earnings were only $0.27 per share compared to the needed $0.355 [5]. - Full Year Diluted EPS: Promised an improving trajectory, but actual EPS was $0.64, down from $0.82 [5]. - Book Value: Management stated it was stable, but it eroded due to over-distribution [5]. Group 3: Underlying Issues - The company faced challenges such as declining GAAP net income, which fell to $84.1 million in 2025 from $92.4 million in 2024, and delays in REO liquidations that locked equity in underperforming assets [7]. - Management admitted to over-distributing capital to investors for multiple quarters, which contributed to the financial strain [7]. - The lawsuit alleges that management recklessly overstated FBRT's ability to maintain the dividend, despite internal challenges undermining the coverage roadmap [9].

Core Viewpoint - A securities fraud class action lawsuit has been filed against PayPal Holdings, Inc. for allegedly making materially false statements regarding its revenue outlook and growth potential during the specified class period [2][4][7]. Group 1: Lawsuit Details - The class period for the lawsuit is from February 25, 2025, to February 2, 2026, and investors have until April 20, 2026, to file for lead plaintiff status [2][7]. - The lawsuit claims that PayPal misrepresented its business operations and growth prospects, leading to a false impression of stability and reliability in its revenue projections [4][7]. Group 2: Stock Performance - PayPal's stock price dropped by $10.63, or 20.3%, closing at $41.70 per share on February 3, 2026, following a surprise leadership change and disappointing earnings report [5]. Group 3: Investor Actions - Investors can seek to be appointed as lead plaintiffs or choose to remain absent class members, with the option to contact Kessler Topaz Meltzer & Check, LLP for legal representation at no cost [6][8][9].